156 related articles for article (PubMed ID: 29496320)
1. Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure.
Joshi SN; Srinivas NR; Parmar DV
Clin Ther; 2018 Mar; 40(3):456-468.e1. PubMed ID: 29496320
[TBL] [Abstract][Full Text] [Related]
2. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Patel MR; Kansagra KA; Parikh DP; Parmar DV; Patel HB; Soni MM; Patil US; Patel HV; Patel JA; Gujarathi SS; Parmar KV; Srinivas NR
Clin Drug Investig; 2018 Jan; 38(1):57-65. PubMed ID: 29022212
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
Jani RH; Kansagra K; Jain MR; Patel H
Clin Drug Investig; 2013 Nov; 33(11):809-16. PubMed ID: 24062180
[TBL] [Abstract][Full Text] [Related]
4. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients.
Miura M; Satoh S; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Suzuki T
Ther Drug Monit; 2008 Feb; 30(1):52-9. PubMed ID: 18223463
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients.
Brooks EK; Tett SE; Isbel NM; McWhinney B; Staatz CE
Ther Drug Monit; 2018 Apr; 40(2):195-201. PubMed ID: 29461443
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment.
Lawitz E; Parmar D; Momin T; Shaikh F; Patel H; Hayes H; Swint K
Clin Pharmacol Drug Dev; 2023 Dec; 12(12):1142-1155. PubMed ID: 37909052
[TBL] [Abstract][Full Text] [Related]
7. Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.
Giri P; Delvadia P; Ladani MK; Prajapati N; Gupta L; Patel N; Joshi V; Giri S; Jain MR; Srinivas NR; Patel PR
Eur J Pharm Sci; 2019 Mar; 130():107-113. PubMed ID: 30633968
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Imatinib Mesylate and Development of Limited Sampling Strategies for Estimating the Area under the Concentration-Time Curve of Imatinib Mesylate in Palestinian Patients with Chronic Myeloid Leukemia.
Adawi DH; Fredj NB; Al-Barghouthi A; Dridi I; Lubada M; Manasra M; Aouam K
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):43-55. PubMed ID: 38006575
[TBL] [Abstract][Full Text] [Related]
9. Limited Sampling Strategies for Estimating Busulfan Area Under the Concentration-Time Curve: Based on Peak and Trough Concentrations in Saliva.
Xu B; Zhou J; Zheng Y; Xu R; Liu Q; Li D; Liu M; Wu X
J Clin Pharmacol; 2024 Jan; 64(1):58-66. PubMed ID: 37697452
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
[TBL] [Abstract][Full Text] [Related]
11. Limited sampling strategies to predict the area under the concentration-time curve for rifampicin.
Medellín-Garibay SE; Correa-López T; Romero-Méndez C; Milán-Segovia RC; Romano-Moreno S
Ther Drug Monit; 2014 Dec; 36(6):746-51. PubMed ID: 24784025
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin Exposure Prediction With a Limited Sampling Strategy.
De Gregori S; Seminari E; Capone M; Giordani P; Bruno R; De Silvestri A
Ther Drug Monit; 2024 Apr; ():. PubMed ID: 38666474
[TBL] [Abstract][Full Text] [Related]
13. Clinically useful limited sampling strategy to estimate area under the concentration-time curve of once-daily tacrolimus in adult Japanese kidney transplant recipients.
Nakazawa R; Yoshiike M; Nozawa S; Aida K; Katsuoka Y; Fujimoto E; Yazawa M; Kikuchi E; Shibagaki Y; Sasaki H
PLoS One; 2019; 14(12):e0225878. PubMed ID: 31825991
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies.
Mueller SC; Drewelow B
Eur J Clin Pharmacol; 2013 May; 69(5):1127-34. PubMed ID: 23131857
[TBL] [Abstract][Full Text] [Related]
15. Strategy for the Prediction of Steady-State Exposure of Digoxin to Determine Drug-Drug Interaction Potential of Digoxin With Other Drugs in Digitalization Therapy.
Srinivas NR
Am J Ther; 2019; 26(1):e54-e65. PubMed ID: 26808357
[TBL] [Abstract][Full Text] [Related]
16. Limited sampling strategy for predicting isoniazid exposure in patients with extrapulmonary tuberculosis.
Alshaikheid M; Chaabane A; Ben Fredj N; Ben Brahim H; Ben Fadhel N; Chadli Z; Slama A; Boughattas NA; Chakroun M; Aouam K
J Clin Pharm Ther; 2020 Jun; 45(3):503-512. PubMed ID: 31833581
[TBL] [Abstract][Full Text] [Related]
17. Validation of a 2-Point Limited Sampling Strategy to Predict the Tacrolimus Area-Under-the-12-Hour-Curve in Kidney Transplant Recipients.
Vadcharavivad S; Susomboon T; Kulabusaya B; Avihingsanon Y; Praditpornsilpa K; Townamchai N
Ther Drug Monit; 2016 Oct; 38(5):614-20. PubMed ID: 27328329
[TBL] [Abstract][Full Text] [Related]
18. Limited sampling strategy models for estimating the AUC of gliclazide in Chinese healthy volunteers.
Huang JH; Wang K; Huang XH; He YC; Li LJ; Sheng YC; Yang J; Zheng QS
Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):123-30. PubMed ID: 22638844
[TBL] [Abstract][Full Text] [Related]
19. Limited-sampling strategy models for estimating the area under the plasma concentration-time curve for amlodipine.
Suarez-Kurtz G; Vicente FL; Ponte CG; Buy VL; Struchiner CJ
Eur J Clin Pharmacol; 1999 Nov; 55(9):651-7. PubMed ID: 10638394
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis.
Vuppalanchi R; González-Huezo MS; Payan-Olivas R; Muñoz-Espinosa LE; Shaikh F; Pio Cruz-Lopez JL; Parmar D
Clin Transl Gastroenterol; 2021 Mar; 12(4):e00327. PubMed ID: 33769355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
